Testing effectiveness (Phase 2)Study completedNCT01323517
What this trial is testing
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Who this might be right for
Melanoma
Memorial Sloan Kettering Cancer Center 26